  It is now widely established that management of lung cancer is much more complex and can not be centered on the binary classification of small-cell versus non-small cell lung cancer ( NSCLC). Lung cancer is now recognized as a highly heterogeneous disease that develops from genetic mutations and gene expression patterns , which initiate uncontrolled cellular growth , proliferation and progression , as well as immune evasion. Accurate biomarker assessment to determine the mutational status of driver mutations such as